当前位置： SCI文献检索 > CURRENT PHARMACEUTICAL DESIGN期刊下所有文献 > Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.

Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.

Abstract：

:P-Glycoprotein (P-gp) is a 170-kDa transmembrane glycoprotein that works as an efflux pump and confers multidrug resistance (MDR) in normal tissues and tumors, including nervous tissues and brain tumors. In the developing telencephalon, the endothelial expression of P-gp, and the subcellular localization of the transporter at the luminal endothelial cell (EC) plasma membrane are early hallmarks of blood-brain barrier (BBB) differentiation and suggest a functional BBB activity that may complement the placental barrier function and the expression of P-gp at the blood-placental interface. In early fetal ages, P-gp has also been immunolocalized on radial glia cells (RGCs), located in the proliferative ventricular zone (VZ) of the dorsal telencephalon and now considered to be neural progenitor cells (NPCs). RG-like NPCs have been found in many regions of the developing brain and have been suggested to give rise to neural stem cells (NSCs) of adult subventricular (SVZ) neurogenic niches. The P-gp immunosignal, associated with RG-like NPCs during cortical histogenesis, progressively decreases in parallel with the last waves of neuroblast migrations, while 'outer' RGCs and the deriving astrocytes do not stain for the efflux transporter. These data suggest that in human glioblastoma (GBM), P-gp expressed by ECs may be a negligible component of tumor MDR. Instead, tumor perivascular astrocytes may dedifferentiate and resume a progenitor-like P-gp activity, becoming MDR cells and contribute, together with perivascular P-gpexpressing glioma stem-like cells (GSCs), to the MDR profile of GBM vessels. In conclusion, the analysis of Pgp immunolocalization during brain development may contribute to identify the multiple cellular sources in the GBM vessels that may be involved in P-gp-mediated chemoresistance and can be responsible for GBM therapy failure and tumor recurrence.

journal_name

Curr Pharm Des

journal_title

Current pharmaceutical design

authors

de Trizio I,Errede M,d'Amati A,Girolamo F,Virgintino D

doi

10.2174/1381612826666200318130625

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

1428-1437

issue

eissn

1381-6128

issn

1873-4286

pii

CPD-EPUB-105348

journal_volume

pub_type

杂志文章

在线工具

Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.